Around the world, researchers are working extremely hard to develop new treatments and interventions for COVID-19 with new clinical trials opening nearly every day. This directory provides you with information, including enrollment detail, about these trials. In some cases, researchers are able to offer expanded access (sometimes called compassionate use) to an investigational drug when a patient cannot participate in a clinical trial.
The information provided here is drawn from ClinicalTrials.gov. If you do not find a satisfactory expanded access program here, please search in our COVID Company Directory. Some companies consider expanded access requests for single patients, even if they do not show an active expanded access listing in this database. Please contact the company directly to explore the possibility of expanded access.
Emergency INDs
To learn how to apply for expanded access, please visit our Guides designed to walk healthcare providers, patients and/or caregivers through the process of applying for expanded access. Please note that given the situation with COVID-19 and the need to move as fast as possible, many physicians are requesting expanded access for emergency use. In these cases, FDA will authorize treatment by telephone and treatment can start immediately. For more details, consult FDA guidance. Emergency IND is the common route that patients are receiving convalescent plasma.
Search Tips
To search this directory, simply type a drug name, condition, company name, location, or other term of your choice into the search bar and click SEARCH. For broadest results, type the terms without quotation marks; to narrow your search to an exact match, put your terms in quotation marks (e.g., “acute respiratory distress syndrome” or “ARDS”). You may opt to further streamline your search by using the Status of the study and Intervention Type options. Simply click one or more of those boxes to refine your search.
Displaying 4 of 4AGIR à Dom
Through its anti-inflammatory role, molecular hydrogen could have a beneficial effect inpreventing the runaway inflammatory reactions that lead to complications of Covid-19.This hypothesis is supported by numerous preclinical and theoretical arguments, as wellas by some Chinese clinical studies (the Chinese guidelines for the management ofCovid-19 recommend the inhalation of hydrogen), a recommendation whose interest has justbeen confirmed by a publication describing the very positive results of a clinical studyin China.Through its anti-inflammatory role, molecular hydrogen could have a beneficial effect inpreventing the runaway inflammatory reactions that lead to complications of Covid-19.The ingestion of water saturated with molecular hydrogen has been the subject of severalclinical studies in other indications than Covid-19, and no side effects of thisingestion have been reported. A recent publication recommends initiating clinical trialsusing a hydrogen fortified beverage.
Liaquat University of Medical & Health Sciences
This study is aimed to investigate the treatment vitamin D3 as complementary therapy withroutine care for early mild symptoms of COVID-19 in outpatients setting.
Egyptian Military Medical Services
The aim of the study is to clinically use bovine Lf as a safe antiviral adjuvant fortreatment and to assess the potential in reducing mortality and morbidity rates inCOVID-19 patients. The study was approved by the ethical committee of the Egyptian Centerfor Research and Regenerative Medicine in 11-5-2020.
University of Toronto
The Açaí trial will be testing if the açaí berry extract, a safe natural product withanti-inflammatory properties, can be used as a treatment option in adult patients withCOVID-19 in the community.